Pharmosa Biopharm Inc. (TPEX:6875)

Pharmosa Biopharm Income Statement

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	67.27	167.57	314.5	-	-
Revenue Growth (YoY)	-59.86%	-46.72%	-	-	-
Cost of Revenue	54.24	40.67	-	-	-
Gross Profit	13.03	126.9	314.5	-	-
Selling, General & Admin	49.23	50.69	40.35	29.22	18.32
Research & Development	366.65	294.79	276.97	242.31	240.81
Operating Expenses	415.89	345.47	317.32	271.53	259.12
Operating Income	-402.86	-218.57	-2.82	-271.53	-259.12
Interest Expense	-2.1	-2.42	-2.86	-0.65	-1.21
Interest & Investment Income	29.85	32.07	9.53	0.5	0.1
Earnings From Equity Investments	-0.9	1.95	5.5	3.93	0.66
Currency Exchange Gain (Loss)	-	19.31	-6.68	1.02	0.2
Other Non Operating Income (Expenses)	-7.84	1.16	5.79	0.23	2.89
EBT Excluding Unusual Items	-383.85	-166.49	8.46	-266.51	-256.48
Gain (Loss) on Sale of Assets	-	-0.34	-	-	-
Other Unusual Items	-	0.18	-	-	-
Pretax Income	-383.85	-166.65	8.46	-266.51	-256.48
Net Income	-383.85	-166.65	8.46	-266.51	-256.48
Net Income to Common	-383.85	-166.65	8.46	-266.51	-256.48
Shares Outstanding (Basic)	129	126	113	99	85
Shares Outstanding (Diluted)	129	126	113	99	85
Shares Change (YoY)	2.23%	11.49%	15.09%	16.02%	78.34%
EPS (Basic)	-2.97	-1.32	0.07	-2.70	-3.02
EPS (Diluted)	-2.97	-1.32	0.07	-2.70	-3.02
Free Cash Flow	-476.18	-292.43	-50.01	-268.47	-240.57
Free Cash Flow Per Share	-3.68	-2.31	-0.44	-2.73	-2.83
Gross Margin	19.38%	75.73%	100.00%	-	-
Operating Margin	-598.88%	-130.44%	-0.90%	-	-
Profit Margin	-570.63%	-99.45%	2.69%	-	-
Free Cash Flow Margin	-707.88%	-174.51%	-15.90%	-	-
EBITDA	-371.37	-205.09	2.99	-266.24	-254.73
EBITDA Margin	-	-122.39%	0.95%	-	-
D&A For EBITDA	31.48	13.48	5.81	5.3	4.39
EBIT	-402.86	-218.57	-2.82	-271.53	-259.12
EBIT Margin	-	-130.44%	-0.90%	-	-
Revenue as Reported	67.27	-	-	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.